Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | ADH1B | P00325 | 2/20 | 0.33 |
| ▸ | ADH1C | P00326 | 2/20 | 0.33 |
| ▸ | ADH1A | P07327 | 2/20 | 0.33 |
| ▸ | ADH4 | P08319 | 2/20 | 0.33 |
| ▸ | ADH7 | P40394 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566312 | 1.00 | TSHR (0.48) | TSHRFAAHTRPV1ADH1BADH1C | |
| SCHEMBL8498824 | 1.00 | TSHR (0.48) | TSHRFAAHTRPV1ADH1BADH1C | |
| SCHEMBL1327553 | 0.92 | TSHR (0.37) | TSHRFAAHTRPV1ADH1BADH1C | |
| SCHEMBL16177605 | 0.88 | CA2 (0.37) | TSHRFAAHTRPV1CA2 | |
| SCHEMBL14834118 | 0.87 | CA2 (0.36) | TSHRCA2 | |
| SCHEMBL9031315 | 0.86 | ADH1B (0.34) | TSHRFAAHTRPV1ADH1BADH1C | |
| SCHEMBL12083670 | 0.86 | ADH1B (0.34) | TSHRFAAHTRPV1ADH1BADH1C | |
| SCHEMBL12083819 | 0.86 | ADH1B (0.34) | TSHRFAAHTRPV1ADH1BADH1C | |
| SCHEMBL9031307 | 0.86 | ADH1B (0.34) | TSHRFAAHTRPV1ADH1BADH1C | |
| SCHEMBL9865913 | 0.86 | ADH1B (0.34) | TSHRFAAHTRPV1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021086610-A1 | COMPOSITIONS AND METHODS OF USE | VERA BIOTECHNOLOGY, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20200046786-A1 | COMPOSITIONS AND METHODS OF USE | Shah, Kirit (US) | 2020-02-13 | — | — | US | disclosed |
| US-10478464-B2 | Compositions and methods of use | Shah, Kirit (US) | 2019-11-19 | — | — | US | disclosed |
| EP-2381950-B1 | hydroxyhexadecanoic acid for the treatment of cancer | VANAS ONCOLOGY (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2381950-A2 | COMPOSITIONS AND METHODS OF USE | Vanas Oncology (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100209543-A1 | COMPOSITIONS AND METHODS OF USE | VANAS ONCOLOGY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209543-A1 | COMPOSITIONS AND METHODS OF USE | VANAS ONCOLOGY (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2010083311-A2 | COMPOSITIONS AND METHODS OF USE | VANAS ONCOLOGY (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209543-A1 | COMPOSITIONS AND METHODS OF USE | MKI67, VHL, CCNC | TSHR 4443/4885FAAH 1231/4885TRPV1 4452/4885 |
| US-20200046786-A1 | COMPOSITIONS AND METHODS OF USE | MKI67, VHL, CCNC | TSHR 4443/4885FAAH 1231/4885TRPV1 4452/4885 |
| US-10478464-B2 | Compositions and methods of use | MKI67, VHL, CCNC | TSHR 4443/4885FAAH 1231/4885TRPV1 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.